Pennsylvania is currently home to 3293 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Philadelphia, Pittsburgh, Hershey and Allentown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515
Recruiting
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The study is expected to last approximately 5 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: University of Pittsburgh Medical Center (UPMC) - Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
Register for Updates
PULSED AF Post-Approval Study
NCT06578104
Recruiting
PULSED AF PAS is a prospective, global, multi-center, non-randomized, observational trial. Subjects will be treated with the PulseSelect™ PFA System and followed through 36 months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Doylestown Health Cardiology a division of Doylestown Health Physicians, Doylestown, Pennsylvania
Conditions: Atrial Fibrillation
Register for Updates
A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma
NCT06550895
Recruiting
The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple myeloma (MM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Multiple Myeloma
Register for Updates
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
NCT06383390
Recruiting
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.
Gender:
ALL
Ages:
45 years and above
Trial Updated:
07/17/2025
Locations: Heritage Valley Multispecialty Group, Inc, Beaver, Pennsylvania
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
Register for Updates
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
NCT06311578
Recruiting
The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Fox Chase Cancer Center, Philadelphia, Pennsylvania
Conditions: Advanced Solid Tumors
Register for Updates
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
NCT06241456
Recruiting
This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in participants with advanced human epidermal growth factor receptor 2 (HER2)-positive or other advanced solid tumors. The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT825 in indication-specific cohorts.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania
Conditions: Advanced Solid Tumor
Register for Updates
Game-Based Intervention to Reduce Alcohol-Related Harms Among Sexual and Gender Minority Youth
NCT06215664
Recruiting
This is a randomized controlled trial to examine the efficacy of a game-based intervention to reduce alcohol-related harms among sexual and gender minority youth.
Gender:
ALL
Ages:
Between 14 years and 18 years
Trial Updated:
07/17/2025
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Alcohol Problem, Harm Reduction, Alcohol-Related Harm
Register for Updates
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
NCT06150157
Recruiting
The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D\[s\]) and optimal dosing schedule(s) of JNJ-88549968, in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s), in part 2 (Cohort Expansion).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Myeloproliferative Disorders, Essential Thrombocythemia, Neoplasms, Myelofibrosis
Register for Updates
Cardiovascular Effects of a Healthy Dietary Pattern Containing Eggs
NCT06120400
Recruiting
This study will examine the effect of a healthy diet containing 2 eggs per day compared to a healthy diet containing 3 eggs per week on biomarkers of heart health after 4 weeks.
Gender:
ALL
Ages:
Between 30 years and 60 years
Trial Updated:
07/17/2025
Locations: The Pennylvania State University, University Park, Pennsylvania
Conditions: Cardiovascular Diseases
Register for Updates
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
NCT06057935
Recruiting
The purpose of this study is to find out whether intraperitoneal or intravenous chemotherapy given after cytoreductive surgery and HIPEC are effective treatments for people with malignant peritoneal mesothelioma. Outcomes will be compared by observing intraperitoneal versus intravenous treatments to analyze if one is better than the other.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Allegheny Health Network (Data Collection Only), Pittsburgh, Pennsylvania
Conditions: Malignant Peritoneal Mesothelioma, Peritoneal Mesothelioma, Mesothelioma, Mesothelioma, Malignant, Malignant Mesothelioma
Register for Updates
A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED
NCT05966493
Recruiting
This study is to evaluate the safety and efficacy of NEXAGON® (lufepirsen ophthalmic gel) (NEXAGON) in subjects with persistent corneal epithelial defects (PCED). The objectives of the study are to evaluate the safety and efficacy of NEXAGON in this population.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
07/17/2025
Locations: Glaukos Investigative Site, Bala-Cynwyd, Pennsylvania
Conditions: Persistent Corneal Epithelial Defect
Register for Updates
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
NCT05818683
Recruiting
The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of JNJ-78278343 and combination agent in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of JNJ-78278343 with the combination agent in Part 2 (dose expansion).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia, Pennsylvania
Conditions: Metastatic Castration-resistant Prostate Neoplasms
Register for Updates